## 2003 DRAFTING REQUEST

#### **Senate Resolution**

Received: 03/02/2004

Received By: pdykman

Wanted: Today

Identical to LRB:

For: Ronald Brown (608) 266-8546

By/Representing: Mnuk, Katie

This file may be shown to any legislator: NO

Drafter: pdykman

May Contact:

Addl. Drafters:

Subject:

Legislature - miscellaneous res.

Extra Copies:

DAK

**Memorials - to Congress** 

Submit via email: YES

Requester's email:

Sen.Brown@legis.state.wi.us

Carbon copy (CC:) to:

Pre Topic:

No specific pre topic given

Topic:

Disparity in the international trade of brand name prescription drugs

**Instructions:** 

See Attached

**Drafting History:** 

Vers. Drafted Reviewed **Typed Proofed Submitted Jacketed** Required /? /1 pdykman wjackson ifrantze sbasford lemery 03/02/2004 03/02/2004 03/02/2004 \_\_\_ 03/02/2004 03/02/2004

FE Sent For:

# 2003 DRAFTING REQUEST

### **Senate Resolution**

Received: 03/02/2004					Received By: pdykman			
Wanted: Today					Identical to LRB:			
For: Ronald Brown (608) 266-8546					By/Representing: Mnuk, Katie			
This file may be shown to any legislator: NO					Drafter: pdykman			
May Contact:					Addl. Drafters:			
Subject:		ature - miscella orials - to Cong			Extra Copies:	DAK		
Submit	via email: <b>YE</b>	S						
Request	er's email:	Sen.Brow	n@legis.sta	te.wi.us				
Carbon	copy (CC:) to	° °						
Pre Top	pic:					•	· · · · · · · · · · · · · · · · · · ·	
No spec	ific pre topic	given						
Topic:								
Disparit	y in the intern	national trade of	brand name	prescription of	lrugs			
Instruc	tions:							
See Atta	ached							
Draftin	g History:							
Vers.	<u>Drafted</u>	Reviewed	Typed	Proofed	Submitted	Jacketed	<u>Required</u>	

FE Sent For:

pdykman wjackson 03/02/2004 03/02/2004

/? /1

sbasford 03/02/2004

jfrantze \_\_\_\_ 03/02/2004 \_\_\_

## 2003 DRAFTING REQUEST

Senate	Res	nlo	tio	n

Received: 03/02/2004	Received By: pdykman			
Wanted: Today	Identical to LRB:			
For: Ronald Brown (608) 266-8546	By/Representing: Mnuk, Katie			
This file may be shown to any legislator: NO	Drafter: pdykman			
May Contact:	Addl. Drafters:			
Subject: Legislature - miscellaneous res.  Memorials - to Congress	Extra Copies: DAK			
Submit via email: YES				
Requester's email: Sen.Brown@legis.state.wi.us				
Carbon copy (CC:) to:				
Pre Topic:				
No specific pre topic given				
Topic:				
Disparity in the international trade of brand name prescription d	rugs			
Instructions:				
See Attached				
Drafting History:				
Vers. Drafted Reviewed Typed Proofed	Submitted Jacketed Required			

FE Sent For:


<END>



## State of Misconsin 2003 - 2004 LEGISLATURE

RB-4402/1 PJD: .... WL-j

## 2003 SENATE RESOLUTION



Relating to: strongly urging Congress and the Administration to address the significant price disparity in the international trade of brand name prescription drugs by creating a safe and legitimate program for prescription drug importation or through negotiated trade agreements with other industrialized 5 nations. Whereas, the practice of medicine has undergone a shift toward utilization of 6 outpatient prescription medications for patients who in previous years would have 7 8 been hospitalized, and therefore prescription drug spending is increasing over that 9 period; and 10 Whereas, prescription drug spending in the United States is increasing by up to twelve percent each year and accounts for approximately eleven percent of all health care spending, exceeding \$200 billion in outpatient prescription drugs in 12 13 2003; and

(1)

Whereas, Americans pay drug prices that are 30 to 300 percent higher than that paid for the same drugs in Europe and other industrialized nations, and Canadian drug prices average 68 percent less than American prices; and

Whereas, the United States provides the world's greatest financial support for discovery of new medicines through research grants; and

Whereas, individuals who pay high prices for prescription drugs may leave

Whereas, individuals who pay high prices for prescription drugs may leave their prescriptions unfilled, thereby compromising their health and leading to more costly medical intervention; and

Whereas, many consumers are seeking less expensive prescription drugs by importing them from other countries; and

Whereas, the importation of prescription drugs by U.S. businesses and consumers is illegal and potentially unsafe because such practice occurs outside all state and federal regulations governing manufacture, distribution, and dispensing of prescription medicines in this country; and

Whereas, all U.S. health care consumers must be assured of a safe and secure system of prescription drug distribution; and

Whereas, licensed and regulated local professionals must remain a critical part of our drug distribution infrastructure; and

Whereas, all purchasers of prescription drugs, including individual consumers, managed care organizations, insurers, and employers, would benefit from a reduction in the cost of prescription drugs in the U.S. now, therefore, be it

Resolved by the senate, That the Wisconsin senate petitions Congress and the Administration to implement a system to allow licensed U.S. pharmacies and distributors to participate in the importation of medications from pharmacies and pharmaceutical wholesalers licensed and regulated in a manner deemed comparable

to the United States, enabling Wisconsin consumers to access lower-cost drugs while

obtaining medicines from local providers; and, be it further

Resolved, That the senate chief clerk provide a copy of this resolution to the

resident of the United States, the Secretary of the U.S. Department of Health and

fuman Services, the Secretary of the Wisconsin Department of Health and Family

services, and to all members of Wisconsin's congressional delegation.

(END)

#### Basford, Sarah

From:

Mnuk, Katie

Sent: To:

Tuesday, March 02, 2004 2:12 PM

LRB.Legal

Subject:

Draft review: LRB 03-4402/1 Topic: Disparity in the international trade of brand name

prescription drugs

It has been requested by <Mnuk, Katie> that the following draft be jacketed for the SENATE:

Draft review: LRB 03-4402/1 Topic: Disparity in the international trade of brand name prescription drugs